Results from prior investigations have demonstrated that FGF21 is significantly elevated in individuals diagnosed with obesity, insulin resistance, T2DM, dyslipidemia and non-alcoholic fatty liver disease [43]. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.